Clinical results of a concomitant boost radiotherapy technique for muscle-invasive bladder cancer

Strahlentherapie und Onkologie

Volumn 184, Issue 6, 2008, Pages 313-318

  Piet, Anna H M ^a   Hulshof, Maarten C C M ^a,c   Pieters, Bradley R ^a   Pos, Floris J ^b   De Reijke, Theo M ^a   Koning, Caro C E ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Concomitant boost; Functional outcome; Invasive bladder cancer; Radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER CAPACITY; CANCER CONTROL; CANCER INVASION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CANCER SURVIVAL; CYSTOSCOPY; DISABILITY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PELVIS; RADIATION DOSE; RETROSPECTIVE STUDY; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYSTOSCOPY; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC IRRADIATION; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; URINARY BLADDER NEOPLASMS;

EID: 44949146538     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-008-1797-3     Document Type: Article

References (41)

1. Baierlein SA, Distel L, Sieber R, et al. Combined effect of tumor necrosis factor-alpha and ionizing radiation on the induction of apoptosis in 5637 bladder carcinoma cells. Strahlenther Onkol 2006;182:467-72.
2. Blank LE, Koedooder K, van Os R, et al. Results of bladder-conserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter. Int J Radiat Oncol Biol Phys 2007;69:454-8.
3. Chahal R, Sundaram SK, Iddenden R, et al. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur Urol 2003;43:246-57.
4. Chen WC, Liaw CC, Chuang CK, et al. Concurrent cisplatin, 5-fluorouracil, leucovorin and radiotherapy for invasive bladder cancer. Int J Radiat Oncol Biol Phys 2003;56:726-33.
5. Cookson MS. The surgical management of muscle invasive bladder cancer: a contemporary review. Semin Radiat Oncol 2005;15:10-8.
6. Coppin CM, Gospodarowicz MK, James K, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:2901-7.
7. Cowan RA, McBain CA, Ryder WDJ, et al. Radiotherapy for muscle-invasive carcinoma of the bladder: results of a randomized trial comparing conventional whole bladder with dose-escalated partial bladder radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:197-207.
8. Dunst J, Diestelhorst A, Kühn R, et al. Organ-sparing treatment in muscle-invasive bladder cancer. Strahlenther Onkol 2005;181:632-7.
9. Gogna NK, Matthews JHL, Turner SL, et al. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localized muscle invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol 2006;81:9-17.
10. Gonzalez Gonzalez D, van der Veen HJ, Ypma AF, et al. Brachytherapy for urinary bladder cancer. Arch Esp Urol 1999;52:655-61.
11. Hayter CR, Paszat LF, Groome PA, et al. The management and outcome of bladder carcinoma in Ontario, 1982-1994. Cancer 2000;89:142-51.
12. Hulshof MC, van Andel G, Bel A, et al. Intravesical markers for delineation of target volume during external focal irradiation of bladder carcinomas. Radiother Oncol 2007;84:49-51.
13. ICRU. Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). ICRU report 62. Bethesda: ICRU, 1999.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Kuczyk M, Turkeri L, Hammerer P, et al. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer? Eur Urol 2003;44:57-64.
16. Majewski W, Maciejewski B, Majewski S, et al. Clinical radiobiology of stage T2-T3 bladder cancer. Int J Radiat Oncol Biol Phys 2004;60:60-70.
17. Marks LB, Carroll PR, Dugan TC, et al. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995; 31:1257-80.
18. Miralbell R, Nouet P, Rouzaud M, et al. Radiotherapy of bladder cancer: relevance of bladder volume changes in planning boost treatment. Int J Radiat Oncol Biol Phys 1998;41:741-6.
19. Moonen L, v.d. Voet H, de Nijs R, et al. Muscle invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment. Radiother Oncol 1998;49:149-55.
20. Moonen LM, v.d. Voet H, Horenblas S, et al. A feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder. Int J Radiat Oncol Biol Phys 1997;37:537-42.
21. Müller A, Diestelhorst A, Kuhnt T, et al. Organ-sparing treatment of advanced bladder cancer. Paclitaxel as a radiosensitizer. Strahlenther Onkol 2007;183:177-83.
22. Nieuwenhuijzen JA, Pos FJ, Moonen LMF, et al. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol 2005;48:239-45.
23. Pos FJ, Hart G, Schneider C, et al. Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose? Int J Radiat Oncol Biol Phys 2006;64:1168-73.
24. Pos FJ, Horenblas S, Dom P, et al. Organ preservation in invasive bladder cancer: brachytherapy, an alternative to cystectomy and combined modality treatment? Int J Radiat Oncol Biol Phys 2005;61:678-86.
25. Pos FJ, Horenblas S, Lebesque J, et al. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer. Int J Radiat Oncol Biol Phys 2004;59:696-705.
26. Pos FJ, Hulshof M, Lebesque J, et al. Adaptive radiotherapy for invasive bladder cancer: a feasibility study. Int J Radiat Oncol Biol Phys 2006;64:862-8.
27. Pos FJ, Tienhoven G, Hulshof MCCM, et al. Concomitant boost radiotherapy for muscle invasive bladder cancer. Radiother Oncol 2003;68:75-80.
28. Quilty PM, Duncan W, Kerr GR. Results of a randomized study to evaluate the influence of dose on morbidity in radiotherapy for bladder cancer. Clin Radiol 1985;36:615-8.
29. Rödel C. Current status of radiation therapy and combined-modality treatment for bladder cancer. Strahlenther Onkol 2004;180:701-9.
30. Rödel C, Weiss C, Sauer R. Combined systemic therapy and radiotherapy for bladder cancer. Strahlenther Onkol 2007;183:Spec No 2:29-31.
31. Scrimger RA, Murtha AD, Parliament MB, et al. Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors. Int J Radiat Oncol Biol Phys 2001;51:23-30.
32. Sengelov L, von der Maase H. Radiotherapy in bladder cancer. Radiother Oncol 1999;52:1-14.
33. Shelley MD, Barber J, Mason MD. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2001;4:CD002079.
34. Steen van der-Banasik EM, Visser AG, Reinders JG, et al. Saving bladders with brachytherapy: implantation technique and results. Int J Radiat Oncol Biol Phys 2002;53:622-9.
35. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
36. UICC. TNM classification of malignant tumours, 6th edn. New York: Wiley-Liss, 2002.
37. Visser O, Nieuwenhuijzen JA, Horenblas S, Members of the Urological Oncology Working Group of the Comprehensive Cancer Centre Amsterdam. Local recurrence after cystectomy and survival of patients with bladder cancer: a population based study in greater Amsterdam. J Urol 2005;174:97-102.
38. Weiss C, Engehausen DG, Krause FS, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007;68:1072-80.
39. Weiss C, Rödel F, Ott O, et al. Pretreatment proliferation and local control in bladder cancer after radiotherapy with or without concurrent chemotherapy. Strahlenther Onkol 2007;183:552-6.
40. Weiss C, Rödel F, Wolf I, et al. Combined-modality treatment and organ preservation in bladder cancer. Strahlenther Onkol 2005;181:213-22.
41. Yavuz AA, Yavuz MN, Ozgur GK, et al. Accelerated superfractionated radiotherapy with concomitant boost for invasive bladder cancer. Int J Radiat Oncol Biol Phys 2003;56:734-45.